港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

恒瑞医药

64.000

-1.200-1.84%

成交量：201.42万

成交额：1.30亿

市值：4,247.68亿

市盈率：56.43

高：65.200

开：65.200

低：63.800

收：65.200

52周最高：95.200

52周最低：52.500

股本：66.37亿

香港流通股本：2.58亿

量比：0.90

换手率：0.78%

股息：- -

股息率：- -

每股收益(LYR):1.134

净资产收益率：14.34%

总资产收益率：8.37%

市净率：6.29

市盈率(LYR):56.43

市销率: 12.09

数据加载中...

总览公司新闻资讯公告

Wellington Management Group LLP增持恒瑞医药(01276)4.96万股每股作价约66.13港元

恒瑞医药(600276.SH)：1类创新药海曲泊帕乙醇胺片新增适应症

恒瑞医药：盐酸伊立替康脂质体注射液（Ⅱ）临床试验获批

恒瑞医药：舒地胰岛素诺利糖肽注射液上市许可申请获国家药监局受理

每日经济新闻

创新赛道升温，恒瑞、百济等药企集体加码研发

世界肾脏日：全球219款肾病药上市！金赛药业BCMA新药与恒瑞医药SGLT2/GLP-1管线竞速

“十五五”开局，恒瑞医药将站在新起点加速推进医药创新

世界肾脏日｜警惕“沉默杀手”，药企竞速“护肾”

21世纪经济报道

14亿欧元BD终止！恒瑞被默克"退货"的背后……

稳字当头：恒瑞医药换届稍欠锐气

冯佶，恒瑞医药女总裁荣登2026“福布斯中国杰出商界女性100”榜单

北京药研汇

今日，康宁杰瑞官宣新CTO！来自恒瑞

恒瑞医药海外大单告吹

股市动态分析

恒瑞医药：注射用SHR-9803获临床试验批准

南方财经网

恒瑞医药：董事会会议通告

香港交易所

每日卖空追踪 | 恒瑞医药 03月11日卖空量成交17.64万股，卖空比例为13.49%

恒瑞医药03月11日主力净流出114.2万元散户资金买入

“医药一哥”被放鸽子，又一个国产创新药BD交易遭“退货”

北京药研汇

翰森制药、恒瑞医药等齐发力，国产GLP-1类减重药加速“破圈”

减重大战再添中国玩家：翰森奥莱泊肽III期成功，国产GLP-1/GIP双靶点加速入场

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/01276/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":64,"timestamp":1773389300003,"preClose":65.2,"halted":0,"volume":2014214,"delay":0,"changeRate":-0.018404907975460166,"floatShares":258000000,"shares":6637000000,"eps":1.1340568645414897,"marketStatus":"休市中","change":-1.2,"latestTime":"03-13 16:08:20","open":65.2,"high":65.2,"low":63.8,"amount":129697137,"amplitude":0.021472,"askPrice":64.2,"askSize":33800,"bidPrice":64,"bidSize":800,"shortable":3,"etf":0,"ttmEps":1.3157418466959525,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":7,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":65.2,"openAndCloseTimeList":[[1773365400000,1773374400000],[1773378000000,1773388800000]],"volumeRatio":0.9001193536395121,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":55.11,"timestamp":1773385200000,"preClose":55.3,"halted":0,"volume":24416400,"delay":0,"premium":"+2.40"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.37%","roe":"14.34%","lyrEps":1.134057,"volumeRatio":0.9001193536395121,"shares":6637000000,"dividePrice":0,"high":65.2,"amplitude":0.021472,"preClose":65.2,"low":63.8,"week52Low":52.5,"pbRate":"6.29","psRate":"12.09","week52High":95.2,"institutionHeld":0,"latestPrice":64,"committee":-0.953757,"eps":1.1340568645414897,"divideRate":0,"volume":2014214,"delay":0,"ttmEps":1.3157418466959525,"open":65.2,"prevYearClose":71.25,"prevWeekClose":65.35,"prevMonthClose":66.5,"prevQuarterClose":71.25,"fiveDayClose":65.35,"twentyDayClose":69.25,"sixtyDayClose":74.7,"earningDate":1774454400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1772208000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-03-13","current":48.641761,"percent":0.024876,"low":46.986716,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"high":65.582363,"avg":55.92933,"sd":4.559039,"marketCap":416170839186.33},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33}],"updateTime":1773487528195},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619919761","title":"Wellington Management Group LLP增持恒瑞医药(01276)4.96万股 每股作价约66.13港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619919761?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 19:19","pubTimestamp":1773400763,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月11日，Wellington Management Group LLP增持恒瑞医药(01276)4.96万股，每股作价66.1267港元，总金额约为327.99万港元。增持后最新持股数目约为2324.44万股，持股比例为9.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU2097828714.EUR","LU1255011170.USD","LU0359201612.USD","LU0359201885.HKD","LU1781817850.SGD","LU1328615791.USD","LU2495084118.USD","LU2097828474.EUR","LU2328871848.SGD","BK1191","LU2543165471.USD","LU1969619763.USD","BK0188","LU2488822045.USD","LU2097828631.EUR","LU1997244956.HKD","LU1655091616.SGD","LU2580892862.HKD","600276","LU0359202008.SGD","LU0405327148.USD","LU2097828557.USD","BK0060","LU1064131003.USD","BK0028","LU0405327494.USD","BK0183","01276","LU1023057109.AUD","LU1820825898.SGD","LU2148510915.USD","BK0239","LU1064130708.USD","LU2580892789.USD","BK0196","LU1580142542.USD","LU1997245177.USD","LU2289578879.USD","LU1146622755.USD","LU2097828805.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2619198064","title":"恒瑞医药(600276.SH)：1类创新药海曲泊帕乙醇胺片新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198064","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198064?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 17:43","pubTimestamp":1773395002,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到国家药品监督管理局的通知，批准公司自主研发的1类创新药海曲泊帕乙醇胺片新增适应症。批准的适应症：本品联合免疫抑制治疗适用于15岁及以上初治重型再生障碍性贫血(SAA)患者。海曲泊帕乙醇胺片于2021年获批上市两个适应症：1.本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者。2.本品适用于对免疫抑制治疗(IST)疗效不佳的重型再生障碍性贫血(SAA)成人患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU2328871848.SGD","600276","LU2148510915.USD","LU2097828557.USD","LU2580892789.USD","LU0359202008.SGD","LU2495084118.USD","LU2097828631.EUR","LU2543165471.USD","LU1328615791.USD","BK0028","LU1655091616.SGD","LU2097828474.EUR","159992","BK1161","LU1820825898.SGD","LU1969619763.USD","LU2097828805.USD","LU1064131003.USD","BK0239","BK1191","LU2097828714.EUR","BK0196","LU1064130708.USD","BK1574","LU0359201885.HKD","01276","BK0183","LU0405327494.USD","LU1580142542.USD","LU0405327148.USD","LU2289578879.USD","LU1997244956.HKD","LU1997245177.USD","BK0188","BK0012","LU2580892862.HKD","LU2488822045.USD","LU1023057109.AUD","LU1146622755.USD","LU1781817850.SGD","LU1997245094.SGD","LU1255011170.USD","06978","BK0060"],"gpt_icon":0},{"id":"2619719872","title":"恒瑞医药：盐酸伊立替康脂质体注射液（Ⅱ）临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719872","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619719872?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 17:39","pubTimestamp":1773394798,"startTime":"0","endTime":"0","summary":"人民财讯3月13日电，恒瑞医药(600276)3月13日公告，近日，子公司上海恒瑞医药有限公司收到国家药品监督管理局核准签发关于盐酸伊立替康脂质体注射液（Ⅱ）的《药物临床试验批准通知书》，将于近期开展临床试验。经查询，伊立替康相关剂型2024年全球总销售额约为3.73亿美元。截至目前，盐酸伊立替康脂质体注射液相关项目累计研发投入约为4.25亿元（未经审计）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671603794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","LU2097828714.EUR","LU1255011170.USD","LU0359201612.USD","LU0359201885.HKD","LU1781817850.SGD","LU1328615791.USD","LU2495084118.USD","LU2097828474.EUR","LU2328871848.SGD","BK1191","LU2543165471.USD","LU1969619763.USD","BK0188","LU2488822045.USD","LU2097828631.EUR","LU1997244956.HKD","LU1655091616.SGD","LU2580892862.HKD","600276","LU0359202008.SGD","LU0405327148.USD","LU2097828557.USD","BK0060","LU1064131003.USD","BK0028","LU0405327494.USD","BK0183","01276","LU1023057109.AUD","LU1820825898.SGD","LU2148510915.USD","BK0239","LU1064130708.USD","LU2580892789.USD","BK0196","LU1580142542.USD","LU1997245177.USD","LU2289578879.USD","LU1146622755.USD","LU2097828805.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2619987211","title":"恒瑞医药：舒地胰岛素诺利糖肽注射液上市许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619987211","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619987211?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 17:39","pubTimestamp":1773394783,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月13日，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，公司舒地胰岛素诺利糖肽注射液的上市许可申请获国家药监局受理。该药品适用于血糖控制不佳的成人2型糖尿病患者，在饮食和运动基础上联合其他口服降糖药物，改善血糖控制。该药品是公司自主研发的由长效基础胰岛素类似物和胰高血糖素样肽-1受体激动剂组成的固定比例复方制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603133671602785.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671602785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1146622755.USD","LU2580892789.USD","LU1997245177.USD","LU0405327148.USD","LU1580142542.USD","LU1820825898.SGD","BK0060","LU1969619763.USD","01276","BK0028","LU1255011170.USD","LU2097828714.EUR","BK0188","LU1781817850.SGD","LU0405327494.USD","LU2148510915.USD","LU2097828805.USD","LU1997244956.HKD","BK0012","LU2543165471.USD","BK0239","BK0183","LU1655091616.SGD","BK0196","LU2289578879.USD","LU1328615791.USD","LU2097828474.EUR","LU0359201885.HKD","LU2097828631.EUR","LU0359201612.USD","LU1023057109.AUD","LU2495084118.USD","LU2328871848.SGD","LU1064130708.USD","LU1997245094.SGD","LU0359202008.SGD","LU2488822045.USD","LU2580892862.HKD","LU2097828557.USD","BK1191","600276","LU1064131003.USD"],"gpt_icon":0},{"id":"2619610511","title":"创新赛道升温，恒瑞、百济等药企集体加码研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2619610511","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619610511?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 15:52","pubTimestamp":1773388350,"startTime":"0","endTime":"0","summary":"值得一提的是，在此背景下，恒瑞、百济等大批药企都表示将持续加大研发，聚焦GLP1、肿瘤、ADC、AI 制药等核心赛道。2月26日，百济神州发布2025年度业绩快报公告。据了解，近年来百济神州研发投入呈持续增长态势，2024年单年研发支出达141.4亿元，2025年全年研发费用为约合人民币154.5亿元，同比增长10%。根据季报公布的数字计算，恒瑞医药累计研发投入已超500亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155524a4661da4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155524a4661da4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","BK1191","BK1574","BK1161","LU0359201612.USD","01276","LU1023057109.AUD"],"gpt_icon":0},{"id":"2619616103","title":"世界肾脏日：全球219款肾病药上市！金赛药业BCMA新药与恒瑞医药SGLT2/GLP-1管线竞速","url":"https://stock-news.laohu8.com/highlight/detail?id=2619616103","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619616103?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 12:28","pubTimestamp":1773376095,"startTime":"0","endTime":"0","summary":"截至2025年的最新评估，全球CKD患者总数约为8.5亿，其中高达90%的个体尚未知晓自身病情。该研究是全球首个在糖尿病肾病人群中完成概念性验证的口服小分子GLP-1受体激动剂，有望为患者提供更便捷的治疗选择。世界肾脏日的年度呼吁不应仅停留于口号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313122912954b8117&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313122912954b8117&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","BK1191","01276","LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD","LU0359201612.USD"],"gpt_icon":0},{"id":"2619161081","title":"“十五五”开局，恒瑞医药将站在新起点加速推进医药创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2619161081","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619161081?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 10:23","pubTimestamp":1773368583,"startTime":"0","endTime":"0","summary":"2026年是“十五五”开局之年，站在新起点，恒瑞医药将紧扣\"十五五\"规划纲要要求，加速推进医药创新。作为国内大型药企，恒瑞医药以创新转型为核心引擎，已构建起以自主原研为驱动的产品与技术体系，公司已有20多款1类创新药获批上市。在肿瘤方面，恒瑞医药形成覆盖七大高发癌种、肿瘤支持治疗及多个重大未满足临床需求领域的系统化布局。如2025年上半年，恒瑞医药创新药销售及许可收入占比突破60%，占公司营业收入比重60.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031310252197b06142&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031310252197b06142&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU1023057109.AUD","LU0359201885.HKD","BK1191","BK1515","LU0359202008.SGD","LU0359201612.USD","LU2543165471.USD","01276","BK1161","09939"],"gpt_icon":0},{"id":"2618902170","title":"世界肾脏日｜警惕“沉默杀手”，药企竞速“护肾”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618902170","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618902170?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 12:03","pubTimestamp":1773288195,"startTime":"0","endTime":"0","summary":"今年3月12日迎来第21个世界肾脏日，主题为“人人享有肾脏健康：关爱生命，守护地球”，强调个体健康与环境保护的双重关注。更值得警惕的是，CKD起病隐匿，早期常无明显症状，被称为“沉默的杀手”。此外，通过肾脏B超检查，能够观察肾脏形态和结构，排查囊肿、结石等问题。在此背景下，国内外药企加速布局肾病赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","01276","LU1023057109.AUD","03692","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","BK1191"],"gpt_icon":0},{"id":"2618902199","title":"14亿欧元BD终止！恒瑞被默克\"退货\"的背后……","url":"https://stock-news.laohu8.com/highlight/detail?id=2618902199","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618902199?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 07:31","pubTimestamp":1773271895,"startTime":"0","endTime":"0","summary":"根据协议条款，恒瑞可获得总计高达14亿欧元的首付款、里程碑付款及销售分成，其中首付款1.6亿欧元在协议生效后即落入恒瑞囊中。02终止是“瘦身计划”一环默克此次终止合作的决策，并非针对恒瑞单一个案。值得注意的是，尽管合作终止，但合同并未约定退款条款。从更宏观的视角看，此次终止合作是默克战略调整的必然结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312073613a4623b0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312073613a4623b0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","01276","LU2543165471.USD","LU0359201885.HKD","BK1191","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2618407549","title":"稳字当头：恒瑞医药换届稍欠锐气","url":"https://stock-news.laohu8.com/highlight/detail?id=2618407549","media":"财中TMT","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618407549?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 18:58","pubTimestamp":1773226708,"startTime":"0","endTime":"0","summary":"3月3日，换届公告披露后的首个交易日，恒瑞医药A股收跌1.71%、港股收跌2.34%。2021年更成为恒瑞医药的大考年。这一年，恒瑞医药失去A股医药市值第一的荣耀。危急关头，已卸任近一年半的创始人孙飘扬，于2021年7月重返恒瑞医药，再度掌舵。财报数据显示，2025年三季度末，恒瑞医药合同负债余额从1.60亿元增至39.71亿元。2026年以来，截至目前，公开信息暂无恒瑞医药对外授权合作的新披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311194427a6b80d81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311194427a6b80d81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201612.USD","LU2543165471.USD","01276","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2618394021","title":"冯佶，恒瑞医药女总裁荣登2026“福布斯中国杰出商界女性100”榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2618394021","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618394021?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 17:55","pubTimestamp":1773222938,"startTime":"0","endTime":"0","summary":"刚刚，恒瑞医药官方发布，2026年3月9日，福布斯正式公布2026“中国杰出商界女性100”榜单，恒瑞医药总裁冯佶女士凭借其卓越的领导力与深厚的行业积淀，荣登2026年榜单，为“她力量”写下生动的时代注脚，也让更多人看见中国女性在医药创新领域持续生长的力量。冯佶，女，1970年出生，籍贯上海，现任恒瑞医药总裁兼首席运营官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031121161297adc483&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031121161297adc483&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","BK1191","01276","LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD","LU0359201612.USD"],"gpt_icon":0},{"id":"2618024919","title":"今日，康宁杰瑞官宣新CTO！来自恒瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2618024919","media":"药渡","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618024919?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 17:20","pubTimestamp":1773220800,"startTime":"0","endTime":"0","summary":"此次重磅人事任命，是康宁杰瑞在核心管理团队建设上的重要布局，恰逢公司从创新研发向商业化落地的关键节点。公告显示，其职业履历亮眼，在加入康宁杰瑞之前，职业生涯长期扎根江苏恒瑞医药及旗下子公司，逐步成长为生物药领域核心管理人才。王宏伟博士也对加入康宁杰瑞表达高度期待，他表示，康宁杰瑞作为行业内极具差异化创新能力与高成长潜力的生物制药公司，在双抗及ADC领域的战略布局和快速推进令其印象深刻。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117471097ad7b04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117471097ad7b04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","BK1191","01276","LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD","LU0359201612.USD"],"gpt_icon":0},{"id":"2618940731","title":"恒瑞医药海外大单告吹","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940731","media":"股市动态分析","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940731?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 17:13","pubTimestamp":1773220389,"startTime":"0","endTime":"0","summary":"大单告吹2023年10月30日，恒瑞医药与德国默克达成一项战略授权协议。HRS-1167片为恒瑞医药自主研发的PARP1小分子抑制剂，属于第二代PARP抑制剂，可治疗多种肿瘤疾病，首选适应症为前列腺癌。近日，默克宣布终止与恒瑞医药围绕PARP1抑制剂HRS-1167的全球授权合作。幸运的是，虽然大单告吹，但1.6亿欧元的首付款在2023年交易交割时已全额到账，且协议中无任何首付款退款条款，这笔钱恒瑞医药无需返还。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117195595486399&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117195595486399&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU0359201885.HKD","LU1023057109.AUD","01276","BK1191","LU0359201612.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2618675910","title":"恒瑞医药：注射用SHR-9803获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618675910","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618675910?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 17:07","pubTimestamp":1773220033,"startTime":"0","endTime":"0","summary":"【恒瑞医药：注射用SHR-9803获临床试验批准】恒瑞医药公告，注射用SHR-9803收到国家药品监督管理局签发的《药物临床试验批准通知书》（受理号：CXSL2501078），同意本品联合阿得贝利单抗±贝伐珠单抗±化疗在晚期恶性实体瘤患者中开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113668861077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828805.USD","BK0188","LU2097828631.EUR","BK0060","LU1023057109.AUD","BK0196","BK0012","LU1580142542.USD","BK0183","LU1255011170.USD","600276","LU1146622755.USD","LU2289578879.USD","LU2097828474.EUR","LU1997245094.SGD","LU1655091616.SGD","01276","BK1191","LU2580892789.USD","LU1997244956.HKD","LU2580892862.HKD","LU2543165471.USD","LU2097828557.USD","LU0359202008.SGD","LU2328871848.SGD","LU0359201612.USD","LU1781817850.SGD","LU0405327148.USD","LU0359201885.HKD","LU1328615791.USD","LU1820825898.SGD","BK0239","LU1064131003.USD","LU0405327494.USD","LU1969619763.USD","LU2097828714.EUR","LU1064130708.USD","LU1997245177.USD","LU2488822045.USD","BK0028","LU2148510915.USD","LU2495084118.USD"],"gpt_icon":0},{"id":"2618940735","title":"恒瑞医药：董事会会议通告","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940735","media":"香港交易所","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940735?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217842,"startTime":"0","endTime":"0","summary":"恒瑞医药于2026年3月11日宣布，将于2026年3月25日（星期三）召开董事会会议，主要议程包括审议及批准公司及其附属公司截至2025年12月31日止年度之全年业绩，并考虑派发末期股息事宜。会议将由董事长孙飘扬先生主持，出席会议的董事会成员包括6名执行董事、1名非执行董事及4名独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031118411497ad8f50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031118411497ad8f50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU1023057109.AUD","01276","LU0359201612.USD","BK1191","LU2543165471.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2618757940","title":"每日卖空追踪 | 恒瑞医药 03月11日卖空量成交17.64万股，卖空比例为13.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618757940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618757940?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217820,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间03月11日，跌0.9%，卖空量成交17.64万股，较上一交易日减少37.8%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163223a460b536&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163223a460b536&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201885.HKD","LU1023057109.AUD","LU2543165471.USD","01276","LU0359201612.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2618940753","title":"恒瑞医药03月11日主力净流出114.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940753?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:15","pubTimestamp":1773216957,"startTime":"0","endTime":"0","summary":"03月11日, 恒瑞医药股价跌0.90%，报收65.85元，成交金额8633.1万元，换手率0.51%，振幅2.11%，量比0.35。恒瑞医药今日主力资金净流出114.2万元，上一交易日主力净流入1296.2万元。该股近5个交易日上涨10.38%，主力资金累计净流入3598.0万元；近20日主力资金累计净流入9178.4万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162056a460abca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162056a460abca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","BK1191","LU0359201612.USD","01276","LU1023057109.AUD"],"gpt_icon":0},{"id":"2618940752","title":"“医药一哥”被放鸽子，又一个国产创新药BD交易遭“退货”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940752","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940752?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:06","pubTimestamp":1773216373,"startTime":"0","endTime":"0","summary":"近年来，中国创新药BD交易市场火热。另有报告显示，2026年1—2月中国创新药BD交易总额达532.76亿美元，交易数量达44笔。近日，知名跨国药企默克宣布终止与“医药一哥”恒瑞医药围绕PARP1抑制剂HRS-1167的全球授权合作。而对于恒瑞医药方面，业内指出，这笔合作终止“有得有失”。恒瑞医药的遭遇并非孤例，BD交易可谓是“冰火两重天”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119104197ad9ac2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031119104197ad9ac2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD","01276","BK1161","LU0359202008.SGD","06978","BK1191","LU1023057109.AUD","BK1515","09939"],"gpt_icon":0},{"id":"2618094075","title":"翰森制药、恒瑞医药等齐发力，国产GLP-1类减重药加速“破圈”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618094075","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618094075?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 11:32","pubTimestamp":1773199961,"startTime":"0","endTime":"0","summary":"据悉，在减重药物领域，GLP-1类药物成为热门赛道，国内一批药企也积极抢占这一赛道，并逐渐迎来收获。除了翰森制药外，还有一批国产GLP-1类新药正在加速推进临床。值得一提的是，目前已有多个国产GLP-1类新药获批上市。从临床推进到上市落地，国产GLP-1类药物的多点突破，彰显了我国生物医药产业的自主创新实力。未来，随着药企持续加大研发投入，聚焦剂型创新、适应症拓展，国产GLP-1类药物将在全球肥胖防控领域发挥更重要的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03692","BK1589","LU2543165471.USD","01276","LU0359201612.USD","BK1583","01801","LU1023057109.AUD","LU0359202008.SGD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2618940751","title":"减重大战再添中国玩家：翰森奥莱泊肽III期成功，国产GLP-1/GIP双靶点加速入场","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940751","media":"E药经理人","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940751?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 21:39","pubTimestamp":1773149950,"startTime":"0","endTime":"0","summary":"中国本土企业在GLP-1双靶点减重药领域正加速追赶全球第一梯队。据悉，奥莱泊肽凭借双靶点协同作用的创新设计，恶心发生率平均不到10%，呕吐发生率平均不到5%。目前，奥莱泊肽计划近期在中国递交新药上市申请，若进展顺利，有望成为中国GLP-1/GIP双靶点前三获批的产品之一。恒瑞医药的HRS9531是GLP-1/GIP双靶点注射剂，减重适应证上市申请已于2025年9月获NMPA受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310214535a45ec777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310214535a45ec777&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1191","BK1583","LU0359202008.SGD","03692","BK1589","LU0359201612.USD","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}